Resistance to transfusion therapy in the hereditary hemorrhagic syndromes has long been known to occur. Lawrence and Johnson (1) in 1941 demonstrated a circulating anticoagulant in a case of classical hemophilia. Numerous reviews on the subject of circulating anticoagulants have recently appeared (2) (3) (4) . Richards and Spaet (5) , and Lewis and Didisheim (6) have been able to produce an antibody directed against antihemophilic globulin (AHG) in animals. These studies give support to the concept of an immunologic mechanism for the production of a circulating anticoagulant in hemophilics. Resistance to transfusion in plasma thromboplastin component deficiency (PTC) has also been reported (3, 7) .
Recently the opportunity arose to study a resistant state in a case of plasma thromboplastin antecedent deficiency (PTA). This case has previously been reported as a demonstration of the steps necessary to correct the hemorrhagic diathesis before and during surgery (8) . The usual techniques for demonstration of a circulating anticoagulant were uniformly unsuccessful in this patient. A modification of the thromboplastin generation test (TGT) was used which enabled us to demonstrate the resistant state in vitro.
METHODS
Whole blood clotting time was done by the Lee-White method (9) . One stage plasma prothrombin time was performed according to Quick's technique (10) , and serum prothrombin time was done by a modification of Quick's method (11) . The thromboplastin generation test was done as described by Biggs and Douglas (12) . The search for circulating anticoagulants was performed by mixing normal and patient's blood and determining the clotting times (13) and serum prothrombin times of such mixtures (4) . Plasma recalcification times of similar mixtures were also performed (3). Heparin protamine titration test was done following the technique of Allen and co-workers (14) .
Case presentation. This case has previously been reported as one of a family demonstrating PTA deficiency (see Table I and Figure 1 ) (15 In August of 1956 she was again admitted to Michael Reese Hospital for removal of a stone in the cystic duct. At this time it was noted that she had a marked resistance to transfusion, and correction of her hemorrhagic diathesis came about only by the use of a modified exchange transfusion procedure. At this time demonstration of a circulating anticoagulant by the usual techniques was unrewarding (see Table II ). Three months after surgery further studies were undertaken to define the state of resistance in this patient.
Special techniques. At the present time the available evidence indicates that the state of resistance in the various hereditary hemorrhagic deficiencies is most likely due to the development of an antibody to the coagulation factor which is lacking. This resistance presumably comes about because of immunization by transfusion of normal blood or plasma. This so-called antibody is usually demonstrated by the anticoagulant effect on normal blood. Some antigen-antibody reactions are demonstrable only by special techniques, one of the most common being incubation at 370 C. We, therefore, undertook to perform the thromboplastin generation test, using mixtures of one part of the patient's reagent to nine parts of the normal reagent. Plasma recalcification times were performed in the same manner. All mixtures and individual reagents were incubated at 370 C. for four hours. The reagents were tested to determine loss of potency and none was found. Both normal and the patient's substrates were used and no difference was found. Four hours was chosen for the incubation time because of technical reasons in doing such a large number of generation studies.
RESULTS
In the technique of plasma recalcification time, mixtures of one part patient's plasma to nine parts normal plasma were incubated at 37°C. for four hours. At half-hourly intervals, tubes were removed and the recalcification time determined. A second series using patient's adsorbed plasma was also examined. Incubation of these mixtures 148 *All addition experiments were performed by adding 0.1 ml. of the reagent to 0.9 ml. of the tested blood.
did not provide any evidence of inhibition of normal plasma. The use of a 50 per cent mixture of plasmas also showed no effect of an anticoagulant on the normal plasma. On the contrary, these 100-1 tests provided evidence of correction of the patient's coagulation defect by normal plasma. A mixture of one part patient's to nine parts normal BaSO4 plasma or normal BaSO4 plasma alone were equally effective in producing correction of the TGT (Figure 1 ). After four hours incubation, the mixture had lost its potency; however, the incubated non-mixed normal BaSO4 plasma was as effective as before (Figure 2 ). Figure 3 demonstrates the results using mixtures of normal and the patient's serum. No loss of thromboplastic activity is evident after incubation. Figure 4 shows that a mixture of normal serum ISO and patient's adsorbed plasma resulted in a marked loss of thromboplastic activity after incubation. Figure 5 demonstrates an experiment designed to rule out any inhibitory effect of the anticoagulant against either AHG or PTC. When the patient's and normal BaSO4 plasma were incubated for four hours, correction in the TGT could be accomplished by addition of normal serum (which does not contain AHG). This then rules out AHG inhibition. In like manner, when a four hour incubation of the patient's plasma and normal serum was tested against normal plasma, correction was again achieved indicating that PTC was not inhibited (normal adsorbed plasma does not contain PTC). Correction by addition of either the patient's plasma or serum could not be obtained.
Precipitation of the anticoagulant from the plasma was accomplished by ammonium sulfate fractionation. A 25 to 33 per cent ammonium sulfate solution produced complete removal of the anticoagulant. Zero to 20 per cent saturation removed only small amounts of the anticoagulant. Rosenthal (16) A heparin-like anticoagulant is ruled out on the basis of a normal protamine titration test and because no abnormalities of the plasma prothrombin time were ever elicited.
Of major interest in this study is the demonstration of a circulating anticoagulant by the use of an incubation technique in the thromboplastin generation test. Bergna and Pavlovsky (7) have shown that small amounts of time may elapse before an inhibitory effect of a circulating anticoagulant can be detected using the plasma recalcification time. No effect on recalcification time was demonstrable after four hours of incubation of reagent from our patient. The more sensitive thromboplastin generation test gave substantial evidence of an inhibitory effect of our patient's plasma after four hours of incubation of mixtures of patient's absorbed plasma with either normal sera or plasma.
The patient was reexamined one year after the initial study and the PTA inhibitor was still demonstrable.
SUMMARY
The demonstration of a circulating anticoagulant in PTA deficiency is described for the first time.
The anticoagulant could only be demonstrated by the use of the thromboplastin generation test after incubation of the patient's plasma with either normal sera or plasma.
The anticoagulant activity is confined to the patient's plasma.
